CellSeed

CellSeed Net Margin

The Net Profit Margin of CellSeed (7776.T) as of Oct 27, 2026 is -1,319.46 %. In the previous year, Net Profit Margin was -444.87 % — a change of 196.59% (lower).

Net Margin

-1,319.46 %

YoY

196.59%

Last updated:

Net Profit Margin of CellSeed is 2025 -1,319.46 % . Net Profit Margin of CellSeed was 2024 -444.87 % . It decreases by 196.59% lower compared to the previous year.

For CellSeed, the net margin of -1,319.5% is down versus -564.6% a few years ago.

The CellSeed Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
12.64 JPY
Jan 1, 2019
-283.66 JPY
Jan 1, 2020
-392.98 JPY
Jan 1, 2021
-564.64 JPY
Jan 1, 2022
-600.88 JPY
Jan 1, 2023
-445.23 JPY
Jan 1, 2024
-444.87 JPY
Jan 1, 2025
-1,319.46 JPY
The CellSeed Net Margin history
YEARNet MarginYoY
-1,319.46 %+196.59%
-444.87 %-0.08%
-445.23 %-25.90%
-600.88 %+6.42%
-564.64 %+43.68%
-392.98 %+38.54%
-283.66 %-2,343.33%
12.64 %-101.11%
-1,136.21 %-19.12%
-1,404.80 %+406.78%
-277.20 %-59.04%
-676.74 %+6,325.38%
-10.53 %-29.97%
-15.04 %-23.86%
-19.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Net Profit Margin of CellSeed is -1,319.46 % in 2025.

Net Profit Margin of CellSeed changed from -444.87 % to -1,319.46 %, representing a 196.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin CellSeed since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's CellSeed with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CellSeed

All Key Metrics — CellSeed